As of September 30, the total of cash and cash equivalents and investments was $262.1M, excluding cash from its China joint venture, Kinnjiu, and is expected to fund current operations into mid-2024. "We continue to make advances with our proprietary programs, and are encouraged by what we’re seeing thus far in the ongoing dose escalation for KIN-2787 monotherapy, our pan-RAF inhibitor," said Nima Farzan, chief executive officer, Kinnate Biopharma Inc. "We are actively investigating multiple targets as part of the Kinnate Discovery Engine and look forward to having a third program enter the clinic next year. We remain well funded to continue to innovate and progress our pipeline of novel small molecule drug candidates."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on KNTE:
- Kinnate Biopharma delays test investor patience, says Piper Sandler
- Kinnate Biopharma provides update on KN-8701 trial
- Kinnate Biopharma Inc. Announces Recent Corporate Updates, Including on the Ongoing KIN-2787 Monotherapy Dose Escalation from Global Phase 1 Trial
- FDA gives Kinnate Biopharma Fast Track designation for KIN-2787
- Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-2787, an Investigational Pan-RAF Inhibitor
